Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1952 1
1957 1
1960 1
1969 2
1975 2
1976 3
1977 2
1978 2
1979 1
1980 1
1982 3
1983 2
1984 2
1985 5
1986 4
1987 8
1988 9
1989 10
1990 12
1991 18
1992 18
1993 20
1994 21
1995 17
1996 21
1997 21
1998 24
1999 21
2000 25
2001 19
2002 41
2003 42
2004 42
2005 55
2006 52
2007 63
2008 54
2009 53
2010 64
2011 51
2012 52
2013 77
2014 62
2015 71
2016 85
2017 75
2018 79
2019 79
2020 89
2021 84
2022 72
2023 58
2024 28

Text availability

Article attribute

Article type

Publication date

Search Results

1,560 results

Results by year

Filters applied: . Clear all
Page 1
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.
Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, Brander D, Chanan-Khan AA, Coutre SE, Davis RS, Eradat H, Fletcher CD, Gaballa S, Ghobadi A, Hamid MS, Hernandez-Ilizaliturri F, Hill B, Kaesberg P, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Mato A, Mosse C, Schuster S, Siddiqi T, Stephens DM, Ujjani C, Wagner-Johnston N, Woyach JA, Ye JC, Dwyer MA, Sundar H. Wierda WG, et al. J Natl Compr Canc Netw. 2022 Jun;20(6):622-634. doi: 10.6004/jnccn.2022.0031. J Natl Compr Canc Netw. 2022. PMID: 35714675
The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly evolved in recent years. ...
The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly e …
Acalabrutinib in treatment-naive chronic lymphocytic leukemia.
Byrd JC, Woyach JA, Furman RR, Martin P, O'Brien S, Brown JR, Stephens DM, Barrientos JC, Devereux S, Hillmen P, Pagel JM, Hamdy A, Izumi R, Patel P, Wang MH, Jain N, Wierda WG. Byrd JC, et al. Blood. 2021 Jun 17;137(24):3327-3338. doi: 10.1182/blood.2020009617. Blood. 2021. PMID: 33786588 Free PMC article. Clinical Trial.
Acalabrutinib has demonstrated significant efficacy and safety in relapsed chronic lymphocytic leukemia (CLL). Efficacy and safety of acalabrutinib monotherapy were evaluated in a treatment-naive CLL cohort of a single-arm phase 1/2 trial (ACE-CL-001). ...
Acalabrutinib has demonstrated significant efficacy and safety in relapsed chronic lymphocytic leukemia (CLL). Efficacy …
Familial chronic lymphocytic leukaemia: a survey and review of published studies.
Yuille MR, Matutes E, Marossy A, Hilditch B, Catovsky D, Houlston RS. Yuille MR, et al. Br J Haematol. 2000 Jun;109(4):794-9. doi: 10.1046/j.1365-2141.2000.02111.x. Br J Haematol. 2000. PMID: 10929032 Free article. Review.
B-cell chronic lymphocytic leukaemia (CLL) is the most common form of leukaemia. To gain insight into the role of inherited factors in the disease, we have conducted a survey of the family histories of 268 CLL patients and have reviewed p
B-cell chronic lymphocytic leukaemia (CLL) is the most common form of leukaemia. To gain insight into the
Chronic Lymphocytic Leukemia: Diagnosis and Treatment.
Strati P, Jain N, O'Brien S. Strati P, et al. Mayo Clin Proc. 2018 May;93(5):651-664. doi: 10.1016/j.mayocp.2018.03.002. Mayo Clin Proc. 2018. PMID: 29728204 Review.
The complexity of the treatment of patients with chronic lymphocytic leukemia has increased substantially over the past several years as a consequence of the advent of novel biological agents such as ibrutinib, idelalisib, and venetoclax, as well as increasin …
The complexity of the treatment of patients with chronic lymphocytic leukemia has increased substantially over the past …
Clinical Risks for Chronic Lymphocytic Leukemia.
Brown JR. Brown JR. J Natl Compr Canc Netw. 2024 Apr;22(3):e247020. doi: 10.6004/jnccn.2024.7020. J Natl Compr Canc Netw. 2024. PMID: 38626793 Review.
Our understanding of risk factors for the development of chronic lymphocytic leukemia (CLL) is still incomplete and includes genetic and environmental factors. ...Agent Orange and glyphosate herbicides have perhaps the most data to support their role. CLL is …
Our understanding of risk factors for the development of chronic lymphocytic leukemia (CLL) is still incomplete and inc …
Familial occurrence of chronic lymphocytic leukaemia in Norway.
Tjønnfjord GE, Jønsson V, Ly BE, Johannesen TB. Tjønnfjord GE, et al. Tidsskr Nor Laegeforen. 2012 Oct 2;132(18):2060-3. doi: 10.4045/tidsskr.11.1350. Tidsskr Nor Laegeforen. 2012. PMID: 23038196 Free article. English, Norwegian.
BACKGROUND: The only known risk factor for chronic lymphocytic leukaemia (CLL) is occurrence of the disease in close relatives. The aim of this study was to determine the frequency of familial chronic lymphocytic leukaemia. MATERIA …
BACKGROUND: The only known risk factor for chronic lymphocytic leukaemia (CLL) is occurrence of the disease in close re …
Treatment Refractoriness in Chronic Lymphocytic Leukemia: Old and New Molecular Biomarkers.
Maher N, Mouhssine S, Matti BF, Alwan AF, Gaidano G. Maher N, et al. Int J Mol Sci. 2023 Jun 20;24(12):10374. doi: 10.3390/ijms241210374. Int J Mol Sci. 2023. PMID: 37373521 Free PMC article. Review.
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. ...Multiple mechanisms are involved in resistance to the BCL2 inhibitor venetoclax, including point mutations that impair drug binding, the upregulation of BCL2-related anti-apop
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. ...Multiple mechanisms are involved in
Familial chronic lymphocytic leukemia.
Goldin LR, Slager SL, Caporaso NE. Goldin LR, et al. Curr Opin Hematol. 2010 Jul;17(4):350-5. doi: 10.1097/MOH.0b013e328338cd99. Curr Opin Hematol. 2010. PMID: 20389242 Free PMC article. Review.
PURPOSE OF REVIEW: Families with multiple individuals affected with chronic lymphocytic leukemia (CLL) and other related B-cell tumors have been described in the literature and strong familial aggregation has been seen in populatio …
PURPOSE OF REVIEW: Families with multiple individuals affected with chronic lymphocytic leukemia (CLL) and other …
Familial chronic lymphocytic leukemia in Israel: A disproportionate distribution among Ashkenazi Jews.
Zada M, Lerner D, Piltz Y, Perry C, Avivi I, Herishanu Y. Zada M, et al. Eur J Haematol. 2017 Jul;99(1):51-55. doi: 10.1111/ejh.12889. Epub 2017 May 3. Eur J Haematol. 2017. PMID: 28370385
BACKGROUND: Relatives of patients with chronic lymphocytic leukemia (CLL) are at increased risk of developing CLL. ...RESULTS: Familial CLL was recorded in 41 cases (12.3%) of the patients. The age at diagnosis was younger in patients with familial
BACKGROUND: Relatives of patients with chronic lymphocytic leukemia (CLL) are at increased risk of developing CLL. ...R …
Anticipation in familial chronic lymphocytic leukaemia.
Yuille MR, Houlston RS, Catovsky D. Yuille MR, et al. Leukemia. 1998 Nov;12(11):1696-8. doi: 10.1038/sj.leu.2401176. Leukemia. 1998. PMID: 9823943
A recent analysis of literature reports of familial clusters of chronic lymphocytic leukaemia (CLL) suggested that affected offspring are diagnosed at an age 21 years less than CLL parents. ...We avoided these potential sources of bias by systematic as …
A recent analysis of literature reports of familial clusters of chronic lymphocytic leukaemia (CLL) suggested th …
1,560 results